Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Acquired by Fmr LLC

Fmr LLC boosted its holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) by 18.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 210,312 shares of the biopharmaceutical company’s stock after buying an additional 32,789 shares during the quarter. Fmr LLC’s holdings in Cara Therapeutics were worth $65,000 at the end of the most recent reporting period.

Separately, Disciplined Growth Investors Inc. MN grew its holdings in shares of Cara Therapeutics by 6.6% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Cara Therapeutics in a report on Monday. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and five have assigned a hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $2.32.

Cara Therapeutics Stock Up 1.4 %

Shares of Cara Therapeutics stock opened at $0.46 on Wednesday. Cara Therapeutics, Inc. has a 12 month low of $0.23 and a 12 month high of $1.15. The stock has a market cap of $25.43 million, a PE ratio of -0.26 and a beta of 0.64. The business has a fifty day simple moving average of $0.30 and a 200-day simple moving average of $0.32.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.